EQS Group-Ad-hoc: Achiko AG / Key word(s): Joint Venture 
Achiko AG: Achiko's joint venture partner obtains a distribution certificate for AptameX, a novel diagnostic test for 
Covid-19 in Indonesia, and commences product registration 
29-Apr-2021 / 06:45 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Achiko's joint venture partner obtains a distribution certificate for AptameX, a novel diagnostic test for Covid-19 in 
Indonesia, and commences product registration 
- Achiko AG's joint venture partner PT Indonesia Farma Medis (IFM) obtains medical device distribution certificate 
- Achiko subsequently commenced product registration with its partners with a view to mid-year commercial product 
availability 
- Achiko to generate revenues on a 50% holding of the joint venture and a 10% licensing fee from gross sales 
Zurich, 29 April 2021 - Achiko AG's (SWX:ACHI, ISIN CH0522213468) joint venture partner PT Indonesia Farma Medis 
("IFM") has been granted a medical device distribution certificate for Indonesia and commences product registration for 
AptameX. 
This certificate will allow for the procurement, storage and distribution of the novel diagnostic test, AptameX 
(formerly Project Gumnuts) in Indonesia. It establishes the foundation for a subsequent product registration 
facilitating the production and sales of the product in Indonesia. Achiko has subsequently commenced product 
registration with its partners with a view to a mid-year commercial product availability. 
To this end, Achiko and IFM are progressing forward with the establishment of the joint venture company PT Achiko 
Medika Indonesia for the production, distribution and marketing of AptameX (formerly Project Gumnuts) in Indonesia. 
Achiko will realise revenues on a 50% holding and earn a 10% licensing fee from gross sales. 
Indonesia is a significant and important market, with over 270 million people spread over 16,000 islands. The joint 
venture meets local ownership and approval requirements, enabling Achiko's solution to provide security for millions of 
Indonesians' lives through facilitating access to several tests a month, each at an affordable price. 
For shareholders, this translates to licensing and profit share incomes from the joint venture established with IFM. 
About Achiko AG 
Achiko creates and develops new innovations in healthcare technology through its biotechnology division, AptameX, and 
its sister digital mobile health technology division, Teman Sehat. The Company has created a unique telehealth 
capability that provides user-friendly diagnostic testing integrated with a digital passport solution for the 
management of Covid-19. 
AptameX comprises of DNA aptamer-based technology that is cost-effective, chemically synthesised and widely applicable 
to the evolving diagnostic field of healthcare. Together with the digital mobile health app Teman Sehat, Achiko is 
developing potential technologies that seek to deliver rapid, affordable diagnostic testing for a range of pathogenic 
diseases and therapeutic indications. The AptameX technology is licensed from Regenacellx.sl and Achiko has exclusive 
commercialisation rights. 
Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul and Singapore. 
Further information can be found at www.achiko.com. 
About PT Indonesia Farma Medis 
PT Indonesia Farma Medis ("IFM") is a medical device and pharmaceutical distribution company with a large network of 
relationships and distribution channels that includes hospitals, pharmacies and clinics across the main islands of 
Indonesia. 
IFM provides supply chain solutions for distributing medical products and helps companies seeking market entry navigate 
the complexities of the Indonesian market. 
https://indofarmamedis.com 
Media contacts: 
ACHIKO AG 
Investor Relations 
E: ir@achiko.com 
Switzerland 
Marcus Balogh 
Farner Consulting Ltd. 
E: achiko@farner.ch 
T: +41 44 266 67 67 
Germany and Austria 
Axel Mühlhaus / Dr Sönke Knop 
edicto GmbH 
E: achiko@edicto.de 
T: +49 69 90 55 05-51 
Disclaimer 
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its 
business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause 
the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any 
future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is 
providing this communication as of this date and does not undertake to update any forward-looking statements contained 
herein as a result of new information, future events or otherwise. 
=---------------------------------------------------------------------------------------------------------------------- 
End of ad hoc announcement 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Achiko AG 
              Tessinerplatz 7 
              8002 Zurich 
              Switzerland 
E-mail:       ir@achiko.com 
Internet:     https://www.achiko.com/ 
ISIN:         CH0522213468 
Valor:        48788430 
Listed:       SIX Swiss Exchange 
EQS News ID:  1190160 
 
End of Announcement EQS Group News Service 
=------------

1190160 29-Apr-2021 CET/CEST


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1190160&application_name=news

(END) Dow Jones Newswires

April 29, 2021 00:48 ET (04:48 GMT)